The fund is a balanced investment solution seeking exposure to our global themes through equity and fixed-income funds. The fund has a flexible mandate which allows up to 60% of the portfolio to be exposed to equities and at least 30% of the portfolio to be exposed to fixed income and/or cash investments. We are active managers and not constrained by stock market indices or benchmarks.
Fund Details
| 1 Year | 3 Year | 5 Year | Inception (1 December 2008) | Annual Compound Growth Rate |
| 15.2% | 29.8% | 20.7% | 188.1% | 6.2% |
All figures are based on the Fund’s O Accumulation class and are inclusive of income distributions and fees.
| Portfolio Breakdown | |
| BlueBox Global Technology | 5.7% |
| Vontobel TwentyFour Strategic Income | 5.7% |
| Vanguard S&P 500 | 5.5% |
| IFSL Titan Global Blue Chip | 5.4% |
| Polar Capital Asian Stars | 5.3% |
| Fermat Cat Bond | 4.9% |
| Titan Core Credit | 4.8% |
| Titan Global Hybrid Capital Bond | 4.8% |
| Polar Capital Artificial Intelligence | 4.7% |
| Ruffer Total Return | 4.7% |
| Schroder Strategic Credit | 4.7% |
| Pacific North of South EM Equity Income Opportunities | 4.1% |
| Vanguard Global Stock Index | 4.1% |
| Titan Global Quality Leaders | 4.1% |
| Vanguard FTSE 100 ETF | 3.8% |
| Jupiter UK Alpha | 3.7% |
| iShares Ultrashort | 3.6% |
| Cash | 3% |
| Vanguard FTSE Developed Europe | 3% |
| KBI Global Sustainable Infrastructure | 2.9% |
| Waverton European Capital Growth | 2.8% |
| iShares MSCI Japan | 2.1% |
| Polar Capital Global Healthcare Select | 2.1% |
| Jupiter Japan Select | 2% |
| Royal London Sterling Extra Yield | 1.9% |
| Polar Capital Biotechnology | 0.6% |
We invest into global trends and themes that we believe will benefit from these long-term changes. These are not passing trends or fads, but ongoing phenomena supported by independent evidence.
